TARGETED THERAPY OF HER2-POSITIVE BREAST CANCER: NEW DRUGS (EVIDENCE-BASED APPROACH)
Abstract
The study objective is an evidence-based approach to assessing efficiency of targeted breast cancer therapy with Pertuzumab, Trastuzumab and Docetaxel. The major studies showing efficiency and safety of such treatment have been analyzed.
About the Authors
A. M. Parsadanyan
Surgut State University; Surgut Regional Clinical Hospital
Russian Federation
Russian Federation
I. A. Chernopyatova
Surgut State University
Russian Federation
Russian Federation
References
1. Гарин А. М., Базин И. С. Справочник по лекарственной терапии солидных опухолей. М. : ИНФОТЕХ ; ЛЕКСРУС, 2015. 529 с.
2. Поддубная И. В., Колядина И. В. Адъювантная химиотерапия раннего рака молочной железы. М. : ГБОУ ДПО РМАПО. 2014. С. 104.
3. Колядина И. В., Поддубная И. В. Современные возможности терапии HER2-положительного рака молочной железы (по материалам клинических исследований) // Современная онкология. 2014. № 4. Т. 1. С. 10-20.
4. Cortés J., Baselga J., Im Y. H. et al. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer // Annals of Oncology. № 24 (10) P. 2630-2635. URL: http://annonc.oxfordjournals.org/content/24/10/2630.full?sid=0ff4b064-122c-43ed-b2cf-c06cc8177b1b (дата обращения: 22.04.2016).
5. Schneeweiss A., Chia S., Hickish T. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) // Annals of Oncology. № 24 (9). P. 2278-2284. URL: http://annonc.oxfordjournals.org/content/24/9/2278.full?sid=0ff4b064-122c-43ed-b2cf-c06cc8177b1b (дата обращения: 22.04.2016).
6. Baselga J., Gelmon K. A., Verma Sh. Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy // Clinical of Oncology. 2010. March 1. Vol. 28. Р. 286-296.
7. Krop I. E., Lin N. U., Blackwell K et al. Трастузумабэмтазин (T-DM1) в сравнении с комбинацией лапатиниба и капецитабина у пациентов с метастазами HER2-положительного рака молочной железы в ЦНС: ретроспективный дополнительный анализ в исследовании EMILIA // Annals of Oncology. Репринт. 2015. Т. 26 (1). С. 113-119.
Review
For citations:
Parsadanyan A.M., Chernopyatova I.A. TARGETED THERAPY OF HER2-POSITIVE BREAST CANCER: NEW DRUGS (EVIDENCE-BASED APPROACH). Vestnik SurGU. Meditsina. 2016;(4 (30)):13-16. (In Russ.)
Views:
141
Email this article 
